Capravirine was a non-nucleoside reverse transcriptase inhibitor which reached phase II trials before development was discontinued by Pfizer.[1][2] Both phase IIb trials which were conducted failed to demonstrate that therapy with capravirine provided any significant advantage over existing triple-drug HIV therapies, and pharmacology studies showed that capravirine may interact with other HIV drugs.[3][4]
References
- ^ PubChem. “Capravirine”. pubchem.ncbi.nlm.nih.gov. Retrieved 2019-06-02.
- ^ “Capravirine – Anti-Retroviral Drug”. Drug Development Technology. Archived from the original on 2019-06-02. Retrieved 2019-06-02.
- ^ “Capravirine – Anti-Retroviral Drug”. Drug Development Technology. Archived from the original on 2019-06-02. Retrieved 2019-06-02.
- ^ “A Study of Capravirine Plus VIRACEPT Plus Two Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected Patients Who Failed Previous Anti-HIV Treatments – Full Text View – ClinicalTrials.gov”. clinicaltrials.gov. 23 June 2005. Retrieved 2019-06-02.